Advertisement

Cell Sensitivity Assays: The MTT Assay

  • Johan van Meerloo
  • Gertjan J. L. Kaspers
  • Jacqueline CloosEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 731)

Abstract

The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is based on the conversion of MTT into formazan crystals by living cells, which determines mitochondrial activity. Since for most cell populations the total mitochondrial activity is related to the number of viable cells, this assay is broadly used to measure the in vitro cytotoxic effects of drugs on cell lines or primary patient cells. In this chapter the protocol of the assay is described including important considerations relevant for each step of the assay as well as its limitations and possible applications.

Key words

MTT 3-[4,5-Dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide Viability assay IC50 LC50 Drug sensitivity assay Cytotoxicity assay 

Notes

Acknowledgments

This work was supported by KiKa “Stichting Kinderen Kankervrij” – Dutch Children Cancer-free foundation and VONK “VUmc Onderzoek Naar Kinderkanker” foundation.

References

  1. 1.
    Kaspers, G.J., Pieters, R., Van Zantwijk, CH., Van Wering, E.R., Van Der Does-Van Den Berg, A., Veerman, A.J. (1998) Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood. 92, 259–266.PubMedGoogle Scholar
  2. 2.
    Salomons, G.S., Smets, L.A., Verwijs-Janssen, M., Hart, A.A., Haarman, E.G., Kaspers, G.J., Wering, E.V., Der Does-Van Den Berg, A.V., Kamps, W.A. (1999) Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia. 13, 1574–1580.PubMedCrossRefGoogle Scholar
  3. 3.
    Kaspers G.J., Veerman A.J., Pieters R, Van Zantwijk CH., Smets L.A., Van Wering E.R., Van Der Does-Van Den Berg A. (1997) In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 90, 2723–2729.PubMedGoogle Scholar
  4. 4.
    Kaspers, G.J., Wijnands, J.J., Hartmann, R., Huismans, L., Loonen, A.H., Stackelberg, A., Henze, G., Pieters, R., Hählen, K., Van Wering, E.R., Veerman, A.J. (2005) Immuno-phenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. Eur J Cancer. 41, 1300–1303.PubMedCrossRefGoogle Scholar
  5. 5.
    Hubeek, I., Peters, G.J., Broekhuizen, R., Zwaan, C.M., Kaaijk, P., van Wering, E.S., Gibson, B.E., Creutzig, U., Janka-Schaub, G.E., den Boer, M.L., Pieters, R., Kaspers, G.J. (2006) In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. Haematologica. 91, 17–23.PubMedGoogle Scholar
  6. 6.
    Oerlemans, R., Franke, N.E., Assaraf, Y.G., Cloos, J., van Zantwijk, I., Berkers, C.R., Scheffer, G.L., Debipersad, K., Vojtekova, K., Lemos, C., van der Heijden, J.W., Ylstra, B., Peters, G.J., Kaspers, G.J., Dijkmans, B.A., Scheper, R.J., Jansen, G. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 112, 2489–2499.PubMedCrossRefGoogle Scholar
  7. 7.
    Klumper E., Pieters R., Veerman A.J., Huismans D.R., Loonen A.H., Hählen K., Kaspers G.J., van Wering E.R., Hartmann R., Henze G. (1995) In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 86, 3861–3868.PubMedGoogle Scholar
  8. 8.
    Kaspers G.J., Veerman A.J., Pieters R, Broekema G.J., Huismans D.R., Kazemier K.M., Loonen A.H., Rottier M.A., van Zantwijk CH., Hählen K. (1994) Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer. 70, 1047–1052.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Johan van Meerloo
  • Gertjan J. L. Kaspers
  • Jacqueline Cloos
    • 1
    • 2
    Email author
  1. 1.Department of Paediatric OncologyVU University Medical CenterAmsterdamThe Netherlands
  2. 2.Department of HaematologyVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations